Age, y |
63±12 |
62±12 |
66±10 |
0.029 |
Male, n (%) |
208 (73) |
158 (72) |
50 (76) |
0.560 |
BMI, kg/m2
|
23.8±3.6 |
23.7±3.6 |
24.1±3.4 |
0.505 |
Persistent AF, n (%) |
131 (446) |
92 (42) |
39 (59) |
0.015 |
CHADS2 score, pts |
1.2±1.2 |
1.1±1.1 |
1.6±1.3 |
0.003 |
CHA2DS2-VASc score, pts |
2.1±1.6 |
2.0±1.5 |
2.6±1.7 |
0.008 |
CHF, n (%) |
79 (28) |
58 (26) |
21 (32) |
0.401 |
HT, n (%) |
121 (43) |
90 (41) |
31 (47) |
0.399 |
Age ≥65, n (%) |
150 (53) |
110 (50) |
40 (61) |
0.137 |
Age ≥75, n (%) |
43 (15) |
29 (13) |
14 (21) |
0.125 |
DM, n (%) |
48 (17) |
32 (15) |
16 (24) |
0.076 |
Stroke/TIA, n (%) |
31 (11) |
19 (9) |
12 (18) |
0.039 |
Vascular disease, n (%) |
13 (5) |
8 (4) |
5 (8) |
0.208 |
Blood test |
|
|
|
|
AST, IU/L |
22.3±11.3 |
21.8±10.0 |
24.2±15.1 |
0.132 |
ALT, IU/L |
21.5±18.9 |
21.8±20.7 |
20.7±10.8 |
0.689 |
Cr, mg/dl |
0.84±0.2 |
0.84±0.2 |
0.86±0.2 |
0.622 |
CrCl, ml/min |
84.5±29.3 |
85.5±29.3 |
81.0±29.5 |
0.271 |
NT-ProBNP, pg/ml |
529±667 |
483±686 |
676±603 |
0.049 |
PT-INR |
1.52±0.82 |
1.53±0.06 |
1.51±0.10 |
0.912 |
APTT, sec |
42.5±10.1 |
42.5±8.8 |
42.7±14.9 |
0.883 |
TTE findings |
|
|
|
|
LVDd, mm |
46.8±6.4 |
46.7±6.5 |
46.8±6.2 |
0.929 |
LVDs, mm |
32.1±7.9 |
32.0±7.7 |
32.5±8.3 |
0.684 |
EF, % |
55.8±9.5 |
55.8±0.6 |
55.8±1.2 |
0.984 |
LAD, mm |
38.6±6.9 |
38.1±7.2 |
40.4±5.7 |
0.013 |
TEE findings |
|
|
|
|
AF at TEE, n (%) |
130 (46) |
93 (42) |
37 (56) |
0.052 |
SEC, n (%) |
56 (20) |
32 (15) |
24 (36) |
<0.001 |
LAA flow velocity, cm/s |
53.2±22.2 |
54.3±22.3 |
49.2±22.3 |
0.101 |
Oral anticoagulants |
|
|
|
|
Dabigatran, n (%) |
85 (29) |
67 (31) |
18 (27) |
0.307 |
Rivaroxaban, n (%) |
59 (21) |
46 (21) |
13 (20) |
|
Apixaban, n (%) |
48 (17) |
32 (15) |
16 (24) |
|
Edoxaban, n (%) |
56 (20) |
47 (21) |
9 (14) |
|
Warfarin, n (%) |
37 (13) |
27 (12) |
10 (15) |
|
Low dose in NOACs, n (%) |
44 (18) |
32 (17) |
12 (21) |
0.420 |
IDR in NOACs, n (%) |
14 (5) |
11 (6) |
3 (5) |
0.915 |
Medication |
|
|
|
|
Beta-blocker, n (%) |
147 (52) |
110 (50) |
37 (56) |
0.405 |
Diuretics, n (%) |
53 (18) |
41 (19) |
12 (18) |
0.921 |
ACEI/ARB, n (%) |
79 (27) |
57 (26) |
22 (33) |
0.251 |
Statin, n (%) |
62 (22) |
46 (21) |
16 (24) |
0.580 |
Antiplatelet, n (%) |
21 (7) |
17 (8) |
4 (6) |
0.636 |
AAD, n (%) |
39 (15) |
26 (12) |
13 (20) |
0.118 |
Procedure |
|
|
|
|
RFCA, n (%) |
181 (71) |
134 (68) |
47 (80) |
0.070 |
Cryoballoon ablation, n (%) |
74 (29) |
62 (84) |
12 (16) |
|
Additional linear ablation |
52 (18) |
37 (17) |
15 (23) |
0.292 |
No. of ECV/patients, n |
2.6±3.2 |
2.6±3.1 |
2.6±3.5 |
0.953 |
UFH/ACT kinetics |
|
|
|
|
Baseline ACT, sec |
154±29 |
156±29 |
146±27 |
0.024 |
Time to reach optimal ACT, sec |
37±26 |
35±25 |
44±30 |
0.018 |
Amount of UFH to reach optimal ACT, IU |
6947±2880 |
6894±2928 |
7121±2714 |
0.576 |
Total amount of UFH, IU |
10162±3838 |
10096±3848 |
10385±3807 |
0.595 |